Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): Reduction in atherosclerosis progression and clinical events

Journal of the American College of Cardiology

Volumn 26, Issue 5, 1995, Pages 1133-1139

  Pitt, Bertram ^a   Mancini, G B John ^a,b   Ellis, Stephen G ^a,c   Rosman, Howard S ^a,d   Park, Jong Soon ^a,e   Mcgovern, Mark E ^a,e  

^a UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c LERNER RESEARCH INSTITUTE   (United States)

^d HENRY FORD HOSPITAL   (United States)

^e BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PRAVASTATIN; TREATMENT OUTCOME;

EID: 0028849703     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/0735-1097(95)00301-0     Document Type: Article

References (36)

1. Design and recruitment in the United States of a multicenter quantitative angiographic trial of pravastatin to limit atherosclerosis in the coronary arteries (PLAC I)
2. Arterial imaging and atherosclerosis reversal
3. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?
4. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease the Scandinavian Simvastatin Survival Study (4S)
5. Serum cholesterol levels after coronary angioplasty in men and women
6. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B
7. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia
8. Dietary guidelines for healthy American adults
9. Automated quantitative coronary arteriography: morphologic and physiologic validation in vivo of a rapid digital angiographic method
10. Advantages and limitations of serial coronary arteriography for the assessment of progression and regression of coronary atherosclerosis
11. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography
12. Prognostic significance of progression of coronary atherosclerosis
13. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts
14. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens
15. Effects of coronary artery disease of lipid-lowering diet, or diet plus cholestyramine
16. Coronary angiographic changes with lovastatin therapy
17. Effects of multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease
18. Effect of simvastatin on coronary atheroma: the Multicenter Anti-Atheroma Study (MAAS)
19. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease?
20. Progression of coronary atherosclerosis: is coronary spasm related to progression?
21. Angiographic progression of coronary artery disease and the development of myocardial infarction
22. Long-term prognosis of medically treated patients with acute myocardial infarction and one-vessel coronary artery disease
23. Effects of pravastatin in patients with serum total cholesterol levels from 52 to 78 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors
24. Pravastatin, lipids, and major coronary events
25. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries
26. Effects of age atherosclerosis hypercholesterolemia and hypertension endothelium-mediated coronary blood flow modulation in humans
27. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease
28. The effect of cholesterol-lowering and anti-oxidant therapy on endotheliumdependent coronary vasomotion
29. Beneficial effects of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolemic patients
30. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia
31. Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases
32. Pravachol decreases platelet thrombus formation in hypercholesterolemic coronary patients in conjunction with improvements in serum lipids
33. Platelet aggregation, coronary artery disease and future coronary events
34. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease
35. Evaluation and Treatment of High Blood Cholesterol in Adults
36. Can lifestyle changes reverse coronary heart disease: the Lifestyle Heart Trial